Marcia Belvin insider trades: CytomX Therapeutics (CTMX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Marcia reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | CTMX | ↓ Sell | 13,884 | $2.69 | $37K | Direct | Jun 17, 2025 (1d) |
| Mar 18, 2025 | CTMX | ↓ Sell | 19,512 | $0.60 | $12K | Direct | Mar 20, 2025 (2d) |
| Aug 20, 2024 | CTMX | ↓ Sell | 4,181 | $1.23 | $5K | Direct | Aug 22, 2024 (2d) |
| Mar 19, 2024 | CTMX | ↓ Sell | 12,795 | $2.09 | $27K | Direct | Mar 21, 2024 (2d) |
| Dec 20, 2023 | CTMX | ↓ Sell | 4,077 | $1.38 | $6K | Direct | Dec 22, 2023 (2d) |
| Sep 22, 2023 | CTMX | ↓ Sell | 4,119 | $1.30 | $5K | Direct | Sep 22, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CTMX insiders
Open-market trades in the last 12 months
About Marcia Belvin's insider trades
Marcia Belvin is SVP, Chief Scientific Officer at CytomX Therapeutics (CTMX). Since Sep 22, 2023, Marcia has reported no open-market purchases and 6 sales worth $92K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CTMX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.